Business
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
DALLAS, May 07, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the company’s multi-agentic A.I. co-scientist platform for oncology research and drug discovery. Future development plans for release in the coming year include three major capability tracks: ZetaSwarm™, an autonomous multi-agent swarm intelligence layer; ZetaOmics™, a real-time computational biology and multi-o
About this update from Lantern Pharma Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/2e6cd33522687902f88451af92ba3102"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HtyvsYywV6ofS1dJ.tYcRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/business-wire.com/2e6cd33522687902f88451af92ba3102","width":480,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/aVXGLi2IcBHMcAKHK87J9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/2e6cd33522687902f88451af92ba3102","width":480,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Planned additions are designed to expand and enhance withZeta.ai’s capabilities, including: real-time, multi-omic computational analyses; simultaneous, highly parallel multi-agentic reasoning, and enterprise-grade institutional deployment.","length":239,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"withZeta.ai is now commercially available with a fully enabled subscription payment model serving the full spectrum of the biomedical research and drug development community — and representing a new, non-dilutive revenue stream for Lantern Pharma shareholders in a market for AI-focused drug development and discovery tools and services valued at nearly $15 billion USD.","length":370,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":609,"olType":false},{"type":"text","content":"DALLAS, May 07, 2026--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the company’s multi-agentic A.I. co-scientist platform for oncology research and drug discovery. Future development plans for release in the coming year include three major capability tracks: ZetaSwarm™, an autonomous multi-agent swarm intelligence layer; ZetaOmics™, a real-time computational biology and multi-omic analytics toolkit that extends withZeta.ai’s existing production foundation of 34 bioinformatics, chemoinformatic, and clinical research tools; and a new suite of enterprise-grade platform features designed for institutional and commercial deployment.","length":772,"tag...